Corcept Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 6/6

Corcept Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 3.3%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 0.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12.6% per jaar. Het rendement op eigen vermogen van Corcept Therapeutics is 22.2%, en het heeft een nettomarge van 22.4%.

Belangrijke informatie

3.3%

Groei van de winst

6.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	12.6%
Rendement op eigen vermogen	22.2%
Nettomarge	22.4%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11

Opbrengsten en kosten

Hoe Corcept Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:CORT Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	629	140	244	231
30 Jun 24	570	125	216	217
31 Mar 24	524	117	192	202
31 Dec 23	482	105	184	184
30 Sep 23	450	91	179	166
30 Jun 23	428	94	169	154
31 Mar 23	414	94	164	144
31 Dec 22	402	101	153	131
30 Sep 22	398	117	143	123
30 Jun 22	392	113	138	118
31 Mar 22	380	112	130	113
31 Dec 21	366	113	122	114
30 Sep 21	353	106	116	114
30 Jun 21	343	98	112	119
31 Mar 21	340	99	107	118
31 Dec 20	354	106	105	115
30 Sep 20	356	109	107	111
30 Jun 20	351	114	104	100
31 Mar 20	335	106	104	95
31 Dec 19	306	94	100	89
30 Sep 19	285	87	95	83
30 Jun 19	268	78	92	80
31 Mar 19	258	76	87	78
31 Dec 18	251	75	81	75
30 Sep 18	238	152	77	70
30 Jun 18	216	148	72	63
31 Mar 18	189	142	66	50
31 Dec 17	159	129	62	40
30 Sep 17	130	35	57	33
30 Jun 17	109	24	52	29
31 Mar 17	93	13	50	26
31 Dec 16	81	8	45	24
30 Sep 16	72	5	42	21
30 Jun 16	64	1	41	18
31 Mar 16	56	-2	38	16
31 Dec 15	50	-6	37	15
30 Sep 15	44	-11	36	15
30 Jun 15	38	-17	36	15
31 Mar 15	32	-22	35	15
31 Dec 14	27	-31	35	18
30 Sep 14	22	-39	34	21
30 Jun 14	17	-44	32	23
31 Mar 14	13	-48	33	23
31 Dec 13	10	-46	31	20

Kwaliteitswinsten: CORT heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (22.4%) CORT } zijn hoger dan vorig jaar (20.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van CORT is de afgelopen 5 jaar met 3.3% per jaar gegroeid.

Versnelling van de groei: De winstgroei van CORT over het afgelopen jaar ( 54.6% ) overtreft het 5-jarig gemiddelde ( 3.3% per jaar).

Winst versus industrie: De winstgroei CORT over het afgelopen jaar ( 54.6% ) overtrof de Pharmaceuticals -sector 36.7%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 22.2% ) van CORT wordt als hoog beschouwd.

Corcept Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 6/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated to Report Q2, 2024 Results on Jul 29, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024

Recent updates

Consensus EPS estimates increase by 21%

Chief Development Officer notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024

Corcept Therapeutics Incorporated to Report Q3, 2024 Results on Oct 30, 2024

Price target increased by 14% to US$74.64

Chief Business Officer & Secretary notifies of intention to sell stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 19%

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Chief Development Officer notifies of intention to sell stock

Consensus EPS estimates increase by 20%

Co-Founder exercised options and sold US$9.2m worth of stock

Price target increased by 20% to US$59.60

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated to Report Q2, 2024 Results on Jul 29, 2024

Chief Business Officer & Secretary notifies of intention to sell stock

Price target increased by 14% to US$49.70

Chief Development Officer notifies of intention to sell stock

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome)

President of Endocrinology notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial

Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024

Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

New minor risk - Shareholder dilution

Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024

Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Chief Accounting Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome

President of Endocrinology notifies of intention to sell stock

President of Endocrinology exercised options and sold US$364k worth of stock

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

President of Endocrinology notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial

Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024

Price target increased by 11% to US$39.60

New minor risk - Share price stability

Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology

Chief Scientific Officer exercised options and sold US$728k worth of stock

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

Chief Development Officer notifies of intention to sell stock

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

President of Corcept Endocrinology notifies of intention to sell stock

Consensus EPS estimates increase by 13%

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Price target increased by 8.1% to US$36.83

President of Corcept Endocrinology notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis

Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023

President of Corcept Endocrinology exercised options and sold US$452k worth of stock

President of Corcept Endocrinology notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

President of Corcept Endocrinology notifies of intention to sell stock

Chief Scientific Officer recently sold US$632k worth of stock

Chief Scientific Officer exercised options and sold US$811k worth of stock

Investor sentiment improves as stock rises 22%

Price target increased by 7.3% to US$32.92

Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023

Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Chief Accounting Officer notifies of intention to sell stock

Chief Business Officer & Secretary recently sold US$1.1m worth of stock